PEG-MGF
PEG-MGF
Also known as: PEGylated MGF, PEG MGF, PEG-Mechano Growth Factor
Overview
Key Facts
Primary Goal: Research and therapeutic applications of PEG-MGF
PEG moiety prevents proteolytic degradation, extending circulating half-life. Retains MGF E-domain activity: activates satellite cells from quiescence into proliferative state.
Dosing Information
of native MGF. The PEG moiety shields the peptide from rapid enzymatic degradation, extending its biological activity from minutes to several hours. This allows for systemic distribution and a more practical dosing protocol while retaining MGF's satellite cell-activating properties.Half-LifeSeveral hours (estimated 4-6 hours due to PEGylation)
100–300 mcg
2-3 times per week, subcutaneous or intramuscular
4-6 weeks on, 2-4 weeks off
Benefits
- Extended satellite cell activation compared to non-PEGylated MGF
- Systemic distribution allows broader anabolic effect across muscle groups
- More practical dosing schedule than native MGF
- Enhanced muscle recovery and growth
- May support repair of damaged muscle tissue from injury or intense training
Side Effects
Mechanism of Action
PEG moiety prevents proteolytic degradation, extending circulating half-life
Retains MGF E-domain activity: activates satellite cells from quiescence into proliferative state
Systemic availability allows binding to IGF-1 receptors across multiple muscle beds
Complements endogenous post-exercise MGF expression for additive satellite cell recruitment
Contraindications
Do not use this peptide if any of the following apply:
- Active malignancy
- Known PEG allergy or anti-PEG antibodies
- Pregnancy or breastfeeding
- History of anaphylaxis to PEGylated compounds
Storage & Reconstitution
Unreconstituted (Powder)
Reconstituted (Mixed)
Research Summary
PEG-MGF was developed to address the impractically short half-life of native MGF. Animal studies demonstrate that PEGylated MGF maintains satellite cell activation capacity while providing sustained plasma levels. Research shows significant improvements in muscle mass and strength in rodent models of muscle injury. No human clinical trials have been conducted, but the PEGylation strategy is well-established in pharmaceutical development (e.g., PEGfilgrastim, PEGinterferon).
Frequently Asked Questions
Common questions about PEG-MGF
UK-Specific Information
Exclusive data points and guidance for UK residents using PEG-MGF
UK Lab Testing
UK Lab Testing
Recommended labs: Medichecks, Thriva (£89-£149 for peptide safety panel)
Why this matters: UK-specific lab testing guidance not available on US competitor sites
Commonly Stacked With
5-Amino-1MQ
Research and therapeutic applications of 5-Amino-1MQ
Ac-SDKP
Research and therapeutic applications of Ac-SDKP
ACE-031
Research and therapeutic applications of ACE-031
Acetyl Hexapeptide-3
Research and therapeutic applications of Acetyl Hexapeptide-3
AHK-Cu
Research and therapeutic applications of AHK-Cu
Alcohol Prep Pads
Research and therapeutic applications of Alcohol Prep Pads
Note: Peptide stacking should only be done under the guidance of a qualified healthcare professional. Individual responses may vary.
Share on TikTok
Generate a trackable link to share this peptide information on TikTok